
Longeveron (LGVN) Stock Forecast & Price Target
Longeveron (LGVN) Analyst Ratings
Bulls say
Longeveron Inc. is at the forefront of developing innovative regenerative medicines, specifically Lomecel-B, which has demonstrated significant safety and efficacy in clinical trials, particularly in treating Hypoplastic Left Heart Syndrome (HLHS) with a remarkable 100% five-year transplant-free survival rate in a Phase 1b study. The ongoing Phase 2b study holds the potential for FDA approval, given that no competing drugs have reached this level of clinical evidence, enhancing the prospect for future revenue generation. Furthermore, a discounted cash flow analysis suggests a substantial upside, indicating substantial growth potential compared to the current share price, supported by the strength of the company's pipeline and successful trial outcomes.
Bears say
Longeveron Inc. has experienced a significant stock depreciation of approximately 56% year-to-date, primarily attributed to concerns regarding unexpected safety signals during the clinical development of its investigational product, Lomecel-B, particularly in patients with Hypoplastic Left Heart Syndrome (HLHS). Additionally, the company faces risks related to the efficacy outcomes of the ongoing ELPIS II study and potential delays in securing necessary funding for further clinical development and U.S. commercialization. Further compounding these challenges are regulatory hurdles, market penetration issues, and potential dilution risks, which collectively contribute to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.
Longeveron (LGVN) Analyst Forecast & Price Prediction
Start investing in Longeveron (LGVN)
Order type
Buy in
Order amount
Est. shares
0 shares